APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sclerotherapy

Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids.

Selected research

Market Outlook & Growth Opportunities

Global Sclerotherapy Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchSclerotherapy Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Sclerotherapy Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Sclerotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sclerotherapy Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Sclerotherapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids.

In Eastern Europe, Sclerotherapy key players include BTG, Kreussler, LGM Pharma, Troikaa, Changan Tianyu group.

Russian is the largest market, with a share about 35%, followed by Ukraine and Poland, having a total share about 35 percent.

Read the full market overview

In terms of product, Detergents is the largest segment, with a share about 90%. And in terms of application, the largest application is Venous Disease, followed by Gastrointestinal Bleeding, Bronchopleural Fistula, Cystic Disease.

This report provides an overview of the global Sclerotherapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sclerotherapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sclerotherapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Sclerotherapy market.

Sclerotherapy Segment by Company

BTG

Kreussler

LGM Pharma

Troikaa

Changan Tianyu group

Bioniche Pharma Group Ltd

Omega Pharmaceuticals

Angiodynamics

ENDO-FLEX

MTW ENDOSKOPIE

Cook Medical

Sclerotherapy Segment by Type

Detergents

Osmotic Agents

Chemical Irritants

Sclerotherapy Segment by Application

Venous Disease

Gastrointestinal Bleeding

Bronchopleural Fistula

Cystic Disease

Sclerotherapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sclerotherapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Sclerotherapy key companies, revenue, market share, and recent developments.

3. To split the Sclerotherapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Sclerotherapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sclerotherapy significant trends, drivers, influence factors in global and regions.

6. To analyze Sclerotherapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sclerotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sclerotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sclerotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sclerotherapy industry.

Chapter 3: Detailed analysis of Sclerotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Sclerotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Sclerotherapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sclerotherapy Industry Trends Table 2. Sclerotherapy Industry Drivers Table 3. Sclerotherapy Industry Opportunities and Challenges Table 4. Sclerotherapy Industry Restraints Table 5. Global Sclerotherapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sclerotherapy Revenue Share by Company (2021-2026) Table 7. Global Sclerotherapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Sclerotherapy Key Company Manufacturing Base & Headquarters Table 9. Global Sclerotherapy Company, Product Type & Application Table 10. Global Sclerotherapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Sclerotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Detergents Table 15. Significant Companies of Osmotic Agents Table 16. Significant Companies of Chemical Irritants Table 17. Global Sclerotherapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Sclerotherapy Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Sclerotherapy Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Sclerotherapy Sales Value Share by Type (2021-2026) Table 21. Global Sclerotherapy Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Venous Disease Table 23. Significant Companies of Gastrointestinal Bleeding Table 24. Significant Companies of Bronchopleural Fistula Table 25. Significant Companies of Cystic Disease Table 26. Global Sclerotherapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Sclerotherapy Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Sclerotherapy Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Sclerotherapy Sales Value Share by Application (2021-2026) Table 30. Global Sclerotherapy Sales Value Share by Application (2027-2032) Table 31. Global Sclerotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Sclerotherapy Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Sclerotherapy Sales Value Share by Region (2021-2026) Table 34. Global Sclerotherapy Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Sclerotherapy Sales Value Share by Region (2027-2032) Table 36. Global Sclerotherapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Sclerotherapy Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Sclerotherapy Sales Value Market Share by Country (2021-2026) Table 39. Global Sclerotherapy Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Sclerotherapy Sales Value Market Share by Country (2027-2032) Table 41. BTG Company Information Table 42. BTG Business Overview Table 43. BTG Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. BTG Sclerotherapy Product Portfolio Table 45. BTG Recent Development Table 46. Kreussler Company Information Table 47. Kreussler Business Overview Table 48. Kreussler Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Kreussler Sclerotherapy Product Portfolio Table 50. Kreussler Recent Development Table 51. LGM Pharma Company Information Table 52. LGM Pharma Business Overview Table 53. LGM Pharma Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. LGM Pharma Sclerotherapy Product Portfolio Table 55. LGM Pharma Recent Development Table 56. Troikaa Company Information Table 57. Troikaa Business Overview Table 58. Troikaa Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Troikaa Sclerotherapy Product Portfolio Table 60. Troikaa Recent Development Table 61. Changan Tianyu group Company Information Table 62. Changan Tianyu group Business Overview Table 63. Changan Tianyu group Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Changan Tianyu group Sclerotherapy Product Portfolio Table 65. Changan Tianyu group Recent Development Table 66. Bioniche Pharma Group Ltd Company Information Table 67. Bioniche Pharma Group Ltd Business Overview Table 68. Bioniche Pharma Group Ltd Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Bioniche Pharma Group Ltd Sclerotherapy Product Portfolio Table 70. Bioniche Pharma Group Ltd Recent Development Table 71. Omega Pharmaceuticals Company Information Table 72. Omega Pharmaceuticals Business Overview Table 73. Omega Pharmaceuticals Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Omega Pharmaceuticals Sclerotherapy Product Portfolio Table 75. Omega Pharmaceuticals Recent Development Table 76. Angiodynamics Company Information Table 77. Angiodynamics Business Overview Table 78. Angiodynamics Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Angiodynamics Sclerotherapy Product Portfolio Table 80. Angiodynamics Recent Development Table 81. ENDO-FLEX Company Information Table 82. ENDO-FLEX Business Overview Table 83. ENDO-FLEX Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. ENDO-FLEX Sclerotherapy Product Portfolio Table 85. ENDO-FLEX Recent Development Table 86. MTW ENDOSKOPIE Company Information Table 87. MTW ENDOSKOPIE Business Overview Table 88. MTW ENDOSKOPIE Sclerotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. MTW ENDOSKOPIE Sclerotherapy Product Portfolio Table 90. MTW ENDOSKOPIE Recent Development Table 91. Cook Medical Company Information Table 92. Cook Medical Business Overview Table 93. Cook Medical Sclerotherapy Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 94. Cook Medical Sclerotherapy Product Portfolio Table 95. Cook Medical Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Sclerotherapy Product Image Figure 2. Global Sclerotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sclerotherapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Sclerotherapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Detergents Image Figure 8. Osmotic Agents Image Figure 9. Chemical Irritants Image Figure 10. Global Sclerotherapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Sclerotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Sclerotherapy Sales Value Share by Type (2021-2032) Figure 13. Venous Disease Image Figure 14. Gastrointestinal Bleeding Image Figure 15. Bronchopleural Fistula Image Figure 16. Cystic Disease Image Figure 17. Global Sclerotherapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Sclerotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Sclerotherapy Sales Value Share by Application (2021-2032) Figure 20. Global Sclerotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Sclerotherapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Sclerotherapy Sales Value (2021-2032) & (US$ Million) Figure 23. North America Sclerotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Sclerotherapy Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Sclerotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Sclerotherapy Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Sclerotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Sclerotherapy Sales Value (2021-2032) & (US$ Million) Figure 29. South America Sclerotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Sclerotherapy Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Sclerotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Sclerotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Sclerotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Sclerotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Detergents
  • Osmotic Agents
  • Chemical Irritants
Applications
  • Venous Disease
  • Gastrointestinal Bleeding
  • Bronchopleural Fistula
  • Cystic Disease
Companies covered
  • BTG
  • Kreussler
  • LGM Pharma
  • Troikaa
  • Changan Tianyu group
  • Bioniche Pharma Group Ltd
  • Omega Pharmaceuticals
  • Angiodynamics
  • ENDO-FLEX
  • MTW ENDOSKOPIE
  • Cook Medical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sclerotherapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sclerotherapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Sclerotherapy Market Dynamics
  1. 2.1 Sclerotherapy Industry Trends
  2. 2.2 Sclerotherapy Industry Drivers
  3. 2.3 Sclerotherapy Industry Opportunities and Challenges
  4. 2.4 Sclerotherapy Industry Restraints
3 Sclerotherapy Market by Company
  1. 3.1 Global Sclerotherapy Company Revenue Ranking in 2025
  2. 3.2 Global Sclerotherapy Revenue by Company (2021-2026)
  3. 3.3 Global Sclerotherapy Company Ranking (2024-2026)
  4. 3.4 Global Sclerotherapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Sclerotherapy Company Product Type and Application
  6. 3.6 Global Sclerotherapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Sclerotherapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Sclerotherapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Sclerotherapy Market by Type
  1. 4.1 Sclerotherapy Type Introduction
  2. 4.1.1 Detergents
  3. 4.1.2 Osmotic Agents
  4. 4.1.3 Chemical Irritants
  5. 4.2 Global Sclerotherapy Sales Value by Type
  6. 4.2.1 Global Sclerotherapy Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Sclerotherapy Sales Value by Type (2021-2032)
  8. 4.2.3 Global Sclerotherapy Sales Value Share by Type (2021-2032)
5 Sclerotherapy Market by Application
  1. 5.1 Sclerotherapy Application Introduction
  2. 5.1.1 Venous Disease
  3. 5.1.2 Gastrointestinal Bleeding
  4. 5.1.3 Bronchopleural Fistula
  5. 5.1.4 Cystic Disease
  6. 5.2 Global Sclerotherapy Sales Value by Application
  7. 5.2.1 Global Sclerotherapy Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Sclerotherapy Sales Value by Application (2021-2032)
  9. 5.2.3 Global Sclerotherapy Sales Value Share by Application (2021-2032)
6 Sclerotherapy Regional Value Analysis
  1. 6.1 Global Sclerotherapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sclerotherapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Sclerotherapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Sclerotherapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sclerotherapy Sales Value (2021-2032)
  7. 6.3.2 North America Sclerotherapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Sclerotherapy Sales Value (2021-2032)
  10. 6.4.2 Europe Sclerotherapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Sclerotherapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Sclerotherapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Sclerotherapy Sales Value (2021-2032)
  16. 6.6.2 South America Sclerotherapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Sclerotherapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Sclerotherapy Sales Value Share by Country, 2025 VS 2032
7 Sclerotherapy Country-level Value Analysis
  1. 7.1 Global Sclerotherapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sclerotherapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Sclerotherapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Sclerotherapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Sclerotherapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Sclerotherapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Sclerotherapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Sclerotherapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Sclerotherapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Sclerotherapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Sclerotherapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Sclerotherapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Sclerotherapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Sclerotherapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Sclerotherapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Sclerotherapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Sclerotherapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Sclerotherapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Sclerotherapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Sclerotherapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Sclerotherapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Sclerotherapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Sclerotherapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Sclerotherapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Sclerotherapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Sclerotherapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Sclerotherapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Sclerotherapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Sclerotherapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Sclerotherapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Sclerotherapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Sclerotherapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Sclerotherapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Sclerotherapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Sclerotherapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BTG
  2. 8.1.1 BTG Company Information
  3. 8.1.2 BTG Business Overview
  4. 8.1.3 BTG Sclerotherapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BTG Sclerotherapy Product Portfolio
  6. 8.1.5 BTG Recent Developments
  7. 8.2 Kreussler
  8. 8.2.1 Kreussler Company Information
  9. 8.2.2 Kreussler Business Overview
  10. 8.2.3 Kreussler Sclerotherapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Kreussler Sclerotherapy Product Portfolio
  12. 8.2.5 Kreussler Recent Developments
  13. 8.3 LGM Pharma
  14. 8.3.1 LGM Pharma Company Information
  15. 8.3.2 LGM Pharma Business Overview
  16. 8.3.3 LGM Pharma Sclerotherapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 LGM Pharma Sclerotherapy Product Portfolio
  18. 8.3.5 LGM Pharma Recent Developments
  19. 8.4 Troikaa
  20. 8.4.1 Troikaa Company Information
  21. 8.4.2 Troikaa Business Overview
  22. 8.4.3 Troikaa Sclerotherapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Troikaa Sclerotherapy Product Portfolio
  24. 8.4.5 Troikaa Recent Developments
  25. 8.5 Changan Tianyu group
  26. 8.5.1 Changan Tianyu group Company Information
  27. 8.5.2 Changan Tianyu group Business Overview
  28. 8.5.3 Changan Tianyu group Sclerotherapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Changan Tianyu group Sclerotherapy Product Portfolio
  30. 8.5.5 Changan Tianyu group Recent Developments
  31. 8.6 Bioniche Pharma Group Ltd
  32. 8.6.1 Bioniche Pharma Group Ltd Company Information
  33. 8.6.2 Bioniche Pharma Group Ltd Business Overview
  34. 8.6.3 Bioniche Pharma Group Ltd Sclerotherapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bioniche Pharma Group Ltd Sclerotherapy Product Portfolio
  36. 8.6.5 Bioniche Pharma Group Ltd Recent Developments
  37. 8.7 Omega Pharmaceuticals
  38. 8.7.1 Omega Pharmaceuticals Company Information
  39. 8.7.2 Omega Pharmaceuticals Business Overview
  40. 8.7.3 Omega Pharmaceuticals Sclerotherapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Omega Pharmaceuticals Sclerotherapy Product Portfolio
  42. 8.7.5 Omega Pharmaceuticals Recent Developments
  43. 8.8 Angiodynamics
  44. 8.8.1 Angiodynamics Company Information
  45. 8.8.2 Angiodynamics Business Overview
  46. 8.8.3 Angiodynamics Sclerotherapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Angiodynamics Sclerotherapy Product Portfolio
  48. 8.8.5 Angiodynamics Recent Developments
  49. 8.9 ENDO-FLEX
  50. 8.9.1 ENDO-FLEX Company Information
  51. 8.9.2 ENDO-FLEX Business Overview
  52. 8.9.3 ENDO-FLEX Sclerotherapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ENDO-FLEX Sclerotherapy Product Portfolio
  54. 8.9.5 ENDO-FLEX Recent Developments
  55. 8.10 MTW ENDOSKOPIE
  56. 8.10.1 MTW ENDOSKOPIE Company Information
  57. 8.10.2 MTW ENDOSKOPIE Business Overview
  58. 8.10.3 MTW ENDOSKOPIE Sclerotherapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MTW ENDOSKOPIE Sclerotherapy Product Portfolio
  60. 8.10.5 MTW ENDOSKOPIE Recent Developments
  61. 8.11 Cook Medical
  62. 8.11.1 Cook Medical Company Information
  63. 8.11.2 Cook Medical Business Overview
  64. 8.11.3 Cook Medical Sclerotherapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cook Medical Sclerotherapy Product Portfolio
  66. 8.11.5 Cook Medical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst